TABLE 3.
Levels of radioactivity in wild-type and Oct1−/− mice 30 min after i.v. injection of [3H]cimetidine, [125I]MIBG, [3H]MPP+, or [14C]choline (1 mg/kg)a
| Drug | Tissue | Mean [3H], [14C], or [125I] concn (ng-eq g−1 or ml−1) ± SD
|
Ratio, Oct1−/−/wt | |
|---|---|---|---|---|
| wt | Oct1−/− | |||
| [3H]MPP+ | Liver | 1,989 ± 752 (7.9 ± 3.1b) | 757 ± 218* (3.1 ± 0.7*) | 0.38 (0.39) |
| Sm. int. | 5.7 ± 2.0c | 3.0 ± 1.1c | 0.52 | |
| Kidney | 2,292 ± 1,341 | 2,219 ± 1,992 | 1.03 | |
| Spleen | 2,736 ± 537 | 3,210 ± 939 | 1.17 | |
| Plasma | 94.9 ± 18.7 | 126 ± 40.5 | 1.32 | |
| [125I]MIBG | Liver | 2,600 ± 680 (10.4 ± 1.49) | 607 ± 135** (2.80 ± 0.65**) | 0.23 (0.27) |
| Sm. int. | 2.09 ± 0.94c | 0.97 ± 0.33c | 0.46 | |
| Kidney | 1,333 ± 236 | 1,145 ± 236 | 0.86 | |
| Spleen | 1,065 ± 136 | 1,175 ± 223 | 1.10 | |
| Plasma | 229 ± 54.7 | 214 ± 43.7 | 0.93 | |
| [3H]cimetidine | Liver | 655 ± 10.7 (2.87 ± 0.08) | 528 ± 85.4 (2.32 ± 0.50) | 0.81 (0.81) |
| Sm. int. | 2.03 ± 0.91c | 3.11 ± 0.36c | 1.53 | |
| Kidney | 1,584 ± 412 | 1,194 ± 473 | 0.75 | |
| Spleen | 202 ± 16.0 | 209 ± 26.8 | 1.03 | |
| Plasma | 333 ± 39.7 | 317 ± 88.1 | 0.95 | |
| [14C]choline | Liver | 13,248 ± 4,056 (58.7 ± 16.9) | 14,000 ± 1,445 (69.3 ± 7.8) | 1.06 (1.18) |
| Sm. int. | 4.8 ± 2.1c | 6.5 ± 4.0c | 1.35 | |
| Kidney | 11,777 ± 1,531 | 10,066 ± 251 | 0.85 | |
| Spleen | 3,804 ± 1,166 | 3,737 ± 968 | 0.98 | |
| Plasma | 619 ± 80.0 | 540 ± 50.4 | 0.87 | |
a
wt, wild type; Sm. int., small intestine; *, P < 0.05; **, P < 0.01. Experiments with cimetidine and MIBG were performed in females (n = 3); experiments with MPP+ and choline were performed in males (n = 4).
b
Mean percentage of administered dose ± SD.
c
Mean percentage of dose in small intestinal contents.